Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?

被引:7
作者
Arsenault, Shane [1 ]
Benoit, Rochelle Y. [2 ]
Clift, Fraser [1 ]
Moore, Craig S. [1 ,2 ]
机构
[1] Mem Univ Newfoundland, Fac Med, Discipline Med Neurol, St John, NF, Canada
[2] Mem Univ Newfoundland, Fac Med, Div Biomed Sci, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada
关键词
Multiple sclerosis; Bruton Tyrosine Kinase inhibitor; c-KIT inhibitor; Expanded disability status scale (EDSS); Annualized relapse rate (ARR); Multiple sclerosis functional composite (MSFC); STEM-CELL FACTOR; X-LINKED AGAMMAGLOBULINEMIA; THERAPEUTIC TARGET; BTK; AUTOIMMUNITY; INFLAMMATION; OCRELIZUMAB; IBRUTINIB; DISEASE;
D O I
10.1016/j.msard.2022.104164
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system accompanied by chronic inflammation, axonal loss, and neurodegeneration. Traditionally, MS has been thought of as a T-cell mediated disease, but research over the past decade has demonstrated the importance of B cells in both acute demyelination and disease progression. The highly selective irreversible Bruton Tyrosine Kinase (BTK) inhibitors evobrutinib, tolebrutinib, and orelabrutinib, and the reversible BTK inhibitor fenebrutinib, all target B-cell activation and aspects of innate immunity, including macrophage and microglia biology. The c-KIT inhibitor masitinib mitigates neuroinflammation by controlling the survival, migration, and degranulation of mast cells, leading to the inhibition of proinflammatory and vasoactive molecular cascades that result from mast cell activation.This article will review and critically appraise the ongoing clinical trials of two classes of receptor tyrosine kinase inhibitors that are emerging as potential medical treatments for the varying subtypes of MS: BTK in-hibitors and c-KIT inhibitors. Specifically, this review will attempt to answer whether BTK inhibitors have measurable positive clinical effects on patients with RRMS, SPMS with relapses, relapse-free SPMS, and PPMS through their effect on MRI T1 lesions; annualized relapse rate; EDSS scale; MSFC score; and time to onset of composite 12-week confirmed disability progression. Additionally, this review will examine the literature to determine if masitinib has positive clinical effects on patients with PPMS or relapse-free SPMS through its effect on EDSS or MSFC scores.
引用
收藏
页数:9
相关论文
共 70 条
[1]  
AB Science, 2020, EFF SAF MAS TREATM P
[2]   Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts [J].
Amankwah, Nana ;
Marrie, Ruth Ann ;
Bancej, Christina ;
Garner, Rochelle ;
Manuel, Douglas G. ;
Wall, Ron ;
Fines, Philippe ;
Bernier, Julie ;
Tu, Karen ;
Reimer, Kim .
HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION IN CANADA-RESEARCH POLICY AND PRACTICE, 2017, 37 (02) :37-48
[3]   Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells [J].
Bame, Eris ;
Tang, Hao ;
Burns, Jeremy C. ;
Arefayene, Million ;
Michelsen, Klaus ;
Ma, Bin ;
Marx, Isaac ;
Prince, Robin ;
Roach, Allie M. ;
Poreci, Urjana ;
Donaldson, Douglas ;
Cullen, Patrick ;
Casey, Fergal ;
Zhu, Jing ;
Carlile, Thomas M. ;
Sangurdekar, Dipen ;
Zhang, Baohong ;
Trapa, Patrick ;
Santoro, Joseph ;
Muragan, Param ;
Pellerin, Alex ;
Rubino, Stephen ;
Gianni, Davide ;
Bajrami, Bekim ;
Peng, Xiaomei ;
Coppell, Alex ;
Riester, Katherine ;
Belachew, Shibeshih ;
Mehta, Devangi ;
Palte, Mike ;
Hopkins, Brian T. ;
Scaramozza, Matthew ;
Franchimont, Nathalie ;
Mingueneau, Michael .
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (06)
[4]   Abnormal B-Cell Cytokine Responses A Trigger of T-Cell Mediated Disease in MS? [J].
Bar-Or, Amit ;
Fawaz, Lama ;
Fan, Boli ;
Darlington, Peter J. ;
Rieger, Aja ;
Ghorayeb, Christine ;
Calabresi, Peter A. ;
Waubant, Emmanuelle ;
Hauser, Stephen L. ;
Zhang, Jiameng ;
Smith, Craig H. .
ANNALS OF NEUROLOGY, 2010, 67 (04) :452-461
[5]   Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition [J].
Bhargava, Pavan ;
Kim, Sol ;
Reyes, Arthur A. ;
Grenningloh, Roland ;
Boschert, Ursula ;
Absinta, Martina ;
Pardo, Carlos ;
Van Zijl, Peter ;
Zhang, Jiangyang ;
Calabresi, Peter A. .
BRAIN, 2021, 144 :1396-1408
[6]   Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort [J].
Bigaut, Kevin ;
Fabacher, Thibaut ;
Kremer, Laurent ;
Ongagna, Jean-Claude ;
Kwiatkowski, Arnaud ;
Sellal, Franois ;
Ferriby, Didier ;
Courtois, Sylvie ;
Vermersch, Patrick ;
Collongues, Nicolas ;
Zephir, Helene ;
De Seze, Jerome ;
Outteryck, Olivier .
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) :729-741
[7]   Stem cell factor and hematopoiesis [J].
Broudy, VC .
BLOOD, 1997, 90 (04) :1345-1364
[8]   Mechanisms underlying mast cell influence on EAE disease course [J].
Brown, MA ;
Tanzola, MB ;
Robbie-Ryan, M .
MOLECULAR IMMUNOLOGY, 2002, 38 (16-18) :1373-1378
[9]   Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].
Burger, J. A. ;
Tedeschi, A. ;
Barr, P. M. ;
Robak, T. ;
Owen, C. ;
Ghia, P. ;
Bairey, O. ;
Hillmen, P. ;
Bartlett, N. L. ;
Li, J. ;
Simpson, D. ;
Grosicki, S. ;
Devereux, S. ;
McCarthy, H. ;
Coutre, S. ;
Quach, H. ;
Gaidano, G. ;
Maslyak, Z. ;
Stevens, D. A. ;
Janssens, A. ;
Offner, F. ;
Mayer, J. ;
O'Dwyer, M. ;
Hellmann, A. ;
Schuh, A. ;
Siddiqi, T. ;
Polliack, A. ;
Tam, C. S. ;
Suri, D. ;
Cheng, M. ;
Clow, F. ;
Styles, L. ;
James, D. F. ;
Kipps, T. J. ;
Keating, Michael ;
Jen, Jie ;
Jindra, Pavel ;
Simkovic, Martin ;
Braester, Andrei ;
Ruchlemer, Rosa ;
Foa, Roberto ;
Semenzato, Gianpietro ;
Hawkins, Timothy ;
Atanasio, Carolina Moreno ;
Demirkan, Fatih ;
Kaynar, Leylagul ;
Pylypenko, Halyna ;
Fox, Christopher ;
Thirman, Michael ;
Campbell, Philip .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437
[10]   Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].
Byrd, John C. ;
Furman, Richard R. ;
Coutre, Steven E. ;
Flinn, Ian W. ;
Burger, Jan A. ;
Blum, Kristie A. ;
Grant, Barbara ;
Sharman, Jeff P. ;
Coleman, Morton ;
Wierda, William G. ;
Jones, Jeffrey A. ;
Zhao, Weiqiang ;
Heerema, Nyla A. ;
Johnson, Amy J. ;
Sukbuntherng, Juthamas ;
Chang, Betty Y. ;
Clow, Fong ;
Hedrick, Eric ;
Buggy, Joseph J. ;
James, Danelle F. ;
O'Brien, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42